^
    1d
    SENTRY-2: A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia (clinicaltrials.gov)
    P2, N=58, Recruiting, Karyopharm Therapeutics Inc | N=118 --> 58 | Trial primary completion date: Apr 2026 --> Jun 2027
    Enrollment change • Trial primary completion date
    |
    Jakafi (ruxolitinib) • Xpovio (selinexor) • Vonjo (pacritinib) • Ojjaara (momelotinib)
    2d
    Momelotinib During and After HCT in Myelofibrosis (clinicaltrials.gov)
    P1, N=28, Recruiting, Massachusetts General Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • ASXL1 (ASXL Transcriptional Regulator 1) • SRSF2 (Serine and arginine rich splicing factor 2) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1) • HLA-B (Major Histocompatibility Complex, Class I, B)
    |
    Ojjaara (momelotinib)
    4d
    M-HArbOr: Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia (clinicaltrials.gov)
    P1, N=18, Not yet recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial primary completion date: Dec 2027 --> Mar 2028
    Trial primary completion date
    |
    azacitidine • Ojjaara (momelotinib)
    1m
    Pharmacologic Inhibition of JAK1/2 Potentiates Aminoglycoside-Induced Ototoxicity. (PubMed, Otol Neurotol)
    JAK1 and JAK2 inhibition worsens cochlear damage in mice exposed to aminoglycosides.
    Journal
    |
    JAK1 (Janus Kinase 1) • CDH2 (Cadherin 2) • CDH3 (Cadherin 3) • CDH23 (Cadherin Related 23)
    |
    Ojjaara (momelotinib)
    2ms
    Current treatments, practical management, and emerging investigational therapies for myelofibrosis. (PubMed, Expert Rev Hematol)
    Equally, there is a major focus on next generation JAK inhibitors and mutant calreticulin antibodies. There is also increasing conversation around the need for novel endpoints, as the limitations of symptom assessment, in particular, become apparent and candidate biomarkers of disease modification emerge.
    Review • Journal
    |
    CALR (Calreticulin)
    |
    CALR mutation
    |
    Jakafi (ruxolitinib) • Vonjo (pacritinib) • Inrebic (fedratinib) • Ojjaara (momelotinib)
    2ms
    IKBKE modulates autophagy and progestin resistance in endometrial cancer. (PubMed, Front Oncol)
    A progestin-resistant EC cell line was established to assess the effects of IKBKE knockdown and treatment with CYT387, a selective IKBKE inhibitor...These findings highlight the crucial role of IKBKE in regulating autophagy and mediating progestin resistance in EC. This study provides new insights into IKBKE as a potential molecular target that contributes to understanding the mechanisms underlying progestin resistance in endometrial cancer.
    Journal
    |
    IKBKE (Inhibitor Of Nuclear Factor Kappa B Kinase Subunit Epsilon)
    |
    Ojjaara (momelotinib)
    2ms
    Momelotinib in VEXAS Syndrome (clinicaltrials.gov)
    P2, N=57, Recruiting, Groupe Francophone des Myelodysplasies | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Ojjaara (momelotinib)
    3ms
    Momelotinib Effectiveness in Myelofibrosis (clinicaltrials.gov)
    P=N/A, N=93, Not yet recruiting, Gruppo Italiano Malattie EMatologiche dell'Adulto
    New trial • Real-world evidence
    |
    Ojjaara (momelotinib)
    3ms
    Development of potent JAK1/2 PROTAC degraders for the treatment of inflammatory bowel diseases. (PubMed, Eur J Med Chem)
    Herein, a novel series of PROTAC degraders based on momelotinib were designed and synthesised...Furthermore, in vivo studies demonstrated that A8 significantly reduced inflammatory responses and colon injury by suppressing the JAK/STAT3 signalling pathway. Overall, A8 represents a novel JAK1/2 degrader as a lead compound for IBD for the first time, which deserves further development.
    Journal
    |
    JAK2 (Janus kinase 2) • IL6 (Interleukin 6) • CRBN (Cereblon) • JAK1 (Janus Kinase 1)
    |
    Ojjaara (momelotinib)
    3ms
    Advancements in myelofibrosis management: a comprehensive analysis of Ojjaara (Momelotinib) therapy and clinical perspectives. (PubMed, Ann Med Surg (Lond))
    This review examines the role of momelotinib in treating MF, focusing on its mechanism, clinical benefits, patient selection criteria, monitoring strategies, potential side effects, and findings from key clinical trials. While promising, careful patient management is essential to minimize adverse effects and optimize the therapeutic benefits of momelotinib in MF treatment.
    Review • Journal
    |
    JAK2 (Janus kinase 2) • JAK1 (Janus Kinase 1)
    |
    Ojjaara (momelotinib)
    4ms
    Population Pharmacokinetics and Exposure-Response Analyses of Momelotinib, Its Active Metabolite (M21), and Total Active Moiety in Myelofibrosis. (PubMed, Clin Pharmacol Ther)
    Greater TAM exposure was significantly associated with lower odds of grade 3/4 anemia and higher odds of any-grade peripheral neuropathy, although the latter was infrequently observed in phase III trials. There was no significant relationship with grade ≥ 3 thrombocytopenia or any-grade diarrhea.
    PK/PD data • Journal
    |
    JAK2 (Janus kinase 2) • ACVR1 (Activin A Receptor Type 1) • CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4)
    |
    Ojjaara (momelotinib)
    5ms
    Efficacy of Momelotinib in Myelofibrosis Patients: Results From a Multicenter Study. (PubMed, Eur J Haematol)
    The safety profile was similar to that reported in clinical trials, with most toxicities of grade I-II. In conclusion, our real-life results support the use of momelotinib as an effective and safe therapeutic option for heavily pre-treated, cytopenic MF patients in real-world clinical practice.
    Clinical • Journal
    |
    ACVR1 (Activin A Receptor Type 1)
    |
    Ojjaara (momelotinib)